Emergex Files a Patent in the USA for its novel Pandemic Flu Vaccine
by Press Release from Outbreak News Today on (#3QX7H)
Emergex Vaccines Holding Limited, a biotechnology company pioneering a new approach to enable synthetic vaccine development in the field of infectious diseases, today announces that it has filed a patent in the USA for its novel pandemic flu vaccine. The patent, entitled, 'Reverse Peptide Vaccines' covers the use of peptides derived from human influenza A, ["]
The post Emergex Files a Patent in the USA for its novel Pandemic Flu Vaccine appeared first on Outbreak News Today.